Bashkim Kadriu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4220097/publications.pdf

Version: 2024-02-01

54 papers	2,358 citations	218677 26 h-index	214800 47 g-index
59 all docs	59 docs citations	59 times ranked	3202 citing authors

#	Article	IF	Citations
1	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. Current Topics in Behavioral Neurosciences, 2022, , 141-167.	1.7	4
2	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. Translational Psychiatry, 2022, 12, 179.	4.8	8
3	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry, 2021, 26, 4085-4095.	7.9	48
4	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Molecular Psychiatry, 2021, 26, 3292-3301.	7.9	57
5	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. International Journal of Neuropsychopharmacology, 2021, 24, 8-21.	2.1	58
6	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. Journal of Affective Disorders, 2021, 280, 136-139.	4.1	14
7	Reply to: â€œLetter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same â€“ A comment on Acevedo-Diaz et al.â€•(Jpsychiatrres-D-21-00121). Journal of Psychiatric Research, 2021, 137, 409-410.	3.1	0
8	The Impact of NMDA Antagonists Ketamine and Prodrug 4-Chlorokynunerine (AV-101) in Subjects With Treatment-Resistant Mood Disorders. Biological Psychiatry, 2021, 89, S7.	1.3	0
9	Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road. Drug Discovery Today, 2021, 26, 2816-2838.	6.4	26
10	Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders, 2020, 263, 568-575.	4.1	59
11	The effects of ketamine on typical and atypical depressive symptoms. Acta Psychiatrica Scandinavica, 2020, 142, 394-401.	4.5	16
12	The Impact of Ketamine and AV-101 on the Kynurenine Pathway in Subjects With Treatment-Resistant Unipolar or Bipolar Depression. Biological Psychiatry, 2020, 87, S74.	1.3	0
13	Can â€˜floatingâ€™ predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. Journal of Psychiatric Research, 2020, 130, 280-285.	3.1	18
14	Prognosis and Improved Outcomes in Major Depression: A Review. Focus (American Psychiatric) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	0.8	21
15	Neurobiological biomarkers of response to ketamine. Advances in Pharmacology, 2020, 89, 195-235.	2.0	21
16	Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. Neuropsychopharmacology, 2020, 45, 982-989.	5.4	37
17	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 417-425.	2.1	42
18	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology, 2020, 45, 1398-1404.	5.4	47

#	Article	IF	Citations
19	Not So Fast. Journal of Clinical Psychiatry, 2020, 81, .	2.2	6
20	The influence of ketamine on drug discovery in depression. Drug Discovery Today, 2019, 24, 2033-2043.	6.4	57
21	A Major Role for the Lateral Habenula in Depressive Illness: Physiologic and Molecular Mechanisms. Frontiers in Psychiatry, 2019, 10, 320.	2.6	50
22	S93. Ketamine Treatment Modulates the Kynurenine and Arginine Pathways in Depressed Unipolar and Bipolar Patients. Biological Psychiatry, 2019, 85, S333.	1.3	0
23	Prognosis and improved outcomes in major depression: a review. Translational Psychiatry, 2019, 9, 127.	4.8	262
24	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. International Journal of Neuropsychopharmacology, 2019, 22, 119-135.	2.1	116
25	Do cognitive and neuropsychological functioning deficits coincide with hippocampal alteration during first-psychotic episode?. CNS Spectrums, 2019, 24, 472-478.	1.2	1
26	Disentangling the association of depression on the anti-fatigue effects of ketamine. Journal of Affective Disorders, 2019, 244, 42-45.	4.1	11
27	Rapid-Acting Antidepressants. , 2019, , 218-240.		0
28	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology, 2018, 38, 243-246.	1.4	3
29	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders, 2018, 231, 51-57.	4.1	62
30	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Molecular Psychiatry, 2018, 23, 1626-1631.	7.9	48
31	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Translational Psychiatry, 2018, 8, 280.	4.8	26
32	F171. Ketamine Modulates Kynurenine Pathway in Mood Disorders: A Longitudinal Structural Equation Model. Biological Psychiatry, 2018, 83, S304-S305.	1.3	0
33	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology, 2018, 235, 3017-3030.	3.1	81
34	Characterizing the course of suicidal ideation response to ketamine. Journal of Affective Disorders, 2018, 241, 86-93.	4.1	44
35	Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs, 2017, 77, 381-401.	10.9	98
36	1004. Clinical Predictors of an Antisuicidal Response to Ketamine. Biological Psychiatry, 2017, 81, S406.	1.3	1

#	Article	IF	Citations
37	1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression. Biological Psychiatry, 2017, 81, S405-S406.	1.3	0
38	330. A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression. Biological Psychiatry, 2017, 81, S135.	1.3	2
39	Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntingtonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2239-2244.	7.1	23
40	Pseudologia fantastica: Forensic and clinical treatment implications. Comprehensive Psychiatry, 2015, 56, 17-20.	3.1	4
41	Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology, 2013, 68, 184-194.	4.1	232
42	DNA methyltransferases1 (DNMT1) and 3a (DNMT3a) colocalize with GAD67â€positive neurons in the GAD67â€GFP mouse brain. Journal of Comparative Neurology, 2012, 520, 1951-1964.	1.6	48
43	Absence of tolerance to the anticonvulsant and neuroprotective effects of imidazenil against DFP-induced seizure and neuronal damage. Neuropharmacology, 2011, 61, 1463-1469.	4.1	8
44	Selective Î±4Î²2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons. Neuropsychopharmacology, 2011, 36, 1366-1374.	5.4	36
45	Acute Imidazenil Treatment after the Onset of DFP-Induced Seizure Is More Effective and Longer Lasting than Midazolam at Preventing Seizure Activity and Brain Neuropathology. Toxicological Sciences, 2011, 120, 136-145.	3.1	21
46	L-methionine decreases dendritic spine density in mouse frontal cortex. NeuroReport, 2010, 21, 543-548.	1.2	16
47	Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacology Biochemistry and Behavior, 2010, 95, 383-389.	2.9	15
48	Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4407-4411.	7.1	102
49	Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage. Toxicology, 2009, 256, 164-174.	4.2	31
50	An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophrenia Research, 2009, 111, 115-122.	2.0	117
51	Imidazenil: A low efficacy agonist at Î±1- but high efficacy at Î±5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology, 2008, 55, 148-153.	4.1	29
52	The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14169-14174.	7.1	26
53	Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18736-18741.	7.1	160
54	Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophrenia Research, 2007, 91, 51-61.	2.0	137